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ABSTRACT
Objective Colorectal cancer (CRC) is a major
contributor to cancer mortality and morbidity. LIM kinase
2 (LIMK2) promotes tumour cell invasion and metastasis.
The objectives of this study were to determine how
LIMK2 expression is associated with CRC progression
and patient outcome, and to use genetically modiﬁed
Drosophila and mice to determine how LIMK2 deletion
affects gastrointestinal stem cell regulation and tumour
development.
Design LIMK2 expression and activity were measured
by immunostaining tumours from CRC-prone mice,
human CRC cell lines and 650 human tumours. LIMK
knockdown in Drosophila or Limk2 deletion in mice
allowed for assessment of their contributions to
gastrointestinal stem cell homeostasis and tumour
development.
Results LIMK2 expression was reduced in intestinal
tumours of cancer-prone mice, as well as in human CRC
cell lines and tumours. Reduced LIMK2 expression and
substrate phosphorylation were associated with shorter
patient survival. Genetic analysis in Drosophila midgut
and intestinal epithelial cells isolated from genetically
modiﬁed mice revealed a conserved role for LIMK2 in
constraining gastrointestinal stem cell proliferation. Limk2
deletion increased colon tumour size in a colitis-
associated colorectal mouse cancer model.
Conclusions This study revealed that LIMK2 expression
and activity progressively decrease with advancing stage,
and supports the hypothesis that there is selective
pressure for reduced LIMK2 expression in CRC to relieve
negative constraints imposed upon gastrointestinal
stem cells.
INTRODUCTION
Colorectal cancer (CRC) is the third most common
form of the disease in men and the second most
common in women worldwide, and is a major
contributor to cancer mortality and morbidity.
Although the possibility exists that the CRC cells
of origin may be derived from reprogrammed
epithelial cells or transdifferentiated bone marrow-
derived cells,1 experimental evidence strongly sup-
ports the conclusion that intestinal crypt stem cells
are the predominant source from which intestinal
tumours emerge.2–5 Therefore, mutations or
changes in gene expression observed in CRC may
promote tumour initiation and growth through
their effects on stem cell homeostasis.
The actomyosin cytoskeleton provides the struc-
tural underpinning that gives cells their shape and
allows them to respond to changes in external
physicomechanical conditions. Importantly, dynamic
reorganisation of cytoskeletal structures allows
tumour cells to invade local tissue and ultimately
metastasise to distant sites.6 As a result, a commonly
held concept is that the expression of actomyosin
regulatory proteins will increase during tumorigenesis
and progression. However, given the multiple roles
the actomyosin cytoskeleton plays in cell homeostasis,
for example, in the apoptosis of human embryonic
stem cells,7 an alternative possibility is that there may
be selection for reduced expression or loss of acto-
myosin regulators in some cancers.
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Signiﬁcance of this study
What is already known on this subject?
▸ LIM kinases are overexpressed in some tumour
types.
▸ They contribute to regulation of actomyosin
cytoskeletal dynamics, and hence play roles in
cell motility, invasion and metastasis.
▸ The possible involvement of LIM kinases in CRC
is unknown.
What are the new ﬁndings?
▸ LIMK2 expression and substrate
phosphorylation progressively decrease with
tumour stage.
▸ Deletion of dLIMK in Drosophila midgut results
in stem cell proliferation and organ thickening.
▸ LIMK2 deletion increases mouse intestinal stem
cell proliferation in vitro.
▸ In the context of a mouse model of
colitis-associated CRC, Limk2 deletion increases
dysplasia and intestinal tumour size.
How might it impact on clinical practice in
the foreseeable future?
▸ This study reveals that actomyosin cytoskeleton
regulators such as LIMK2 may have patterns of
expression in CRC distinct from other tumour
types including breast and prostate, meaning
that drugs targeting the cytoskeleton would be
likely to have context-dependent effects.
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The LIM kinase family consists of two members; LIM kinase
1 (LIMK1) and LIM kinase 2 (LIMK2), which play central roles
in RhoGTPase regulation of the actin cytoskeleton by phosphor-
ylating coﬁlin proteins on Serine3 and inactivating their ﬁla-
mentous actin severing activity.8 LIMK1 and LIMK2 have 50%
overall identity and 70% identity in their kinase domains, and
are regulated through activation loop phosphorylation by
RhoGTPase effector kinases including ROCK, PAK and
MRCK.8 LIM kinases act as central network hubs in the regula-
tion of cytoskeletal dynamics and have been proposed to be
attractive potential cancer drug targets.9 Consistent with a posi-
tive role in cancer, expression of LIMK1 has been reported to
be elevated in breast,10 11 malignant melanoma12 and prostate13
tumours. However, there have been no studies reported to date
that examined the expression of LIM kinases in CRC.
In this study, we found that LIMK2 expression is reduced in
intestinal tumours from genetically modiﬁed mice, and in
human CRC cell lines and tumours. Protein levels were progres-
sively lower with advancing tumour grade, and reduced LIMK2
expression or substrate protein phosphorylation were each asso-
ciated with shorter patient survival times. Increased LIMK2 pro-
moter methylation was observed in tumours relative to patient
matched normal tissue. Using genetic methods, we identiﬁed a
repressive role for LIMK2 in intestinal stem cell proliferation in
Drosophila melanogaster and in mice. Using a mouse model of
colitis-associated CRC, we determined that LIM kinase 2 knock-
out (Limk2-KO) mice had increased intestinal tumour size and
dysplasia. These data support the hypothesis that there is select-
ive pressure for reduced LIMK2 expression in CRC to relieve
negative constraints imposed on gastrointestinal stem cells.
MATERIALS AND METHODS
Cell culture
Mouse embryo ﬁbroblast cells were isolated and cultured as
described in D’Abaco and Olson.14 Intestinal epithelial cultures
were isolated and cultured as described in Sato et al.15
Colorectal tumour cell lines were maintained, and cell lysates
prepared, as described in Emaduddin et al.16
Promoter methylation
For de-novo methyltransferase inhibitor treatments, SW48 cells
were plated in six-well plates at 2×105 per well. The following
day, RG108 (100 mM ﬁnal), 5-azacytidine (5-Aza) (10 mM ﬁnal)
or 1% dimethyl sulfoxide vehicle (v/v) were diluted in
Dulbecco’s modiﬁed eagle medium supplemented with 10% fetal
calf serum and applied to cells for 48 h at 37°C. Genomic DNA
from cell lines or tissues was prepared using a QIAamp DNA
Mini Kit (Qiagen). Bisulphite conversion of genomic DNA was
performed using the EZ DNA Methylation-Gold Kit (Zymo
Research), followed by PCR using custom-designed primers
(Invitrogen). PCR products were puriﬁed using the QIAquick
PCR Puriﬁcation Kit (Qiagen) and cloned using the 2.1-TOPO
vector, before transformation into TOP10 Escherichia coli
(Invitrogen). Blue/white screening was utilised to select positive
colonies for DNA isolation and sequencing. Sequencing analysis
was done using CLC Genomics V.5.0 software.
Cell extraction and immunoblotting
Whole cell lysates were prepared and western blotted as
described previously.17 Primary antibodies used were routinely
used at 1:1000 for western blotting. Antibodies used were:
coﬁlin (Cell Signaling Technology); LIMK1 (Cell Signaling
Technology); LIMK2 (Santa Cruz Biotechnology, Inc.);
α-tubulin (σ-Aldrich); phospho-coﬁlin (Cell Signaling
Technology); β-catenin (BD Biosciences); GFP (Abcam); Olfm4
(Abcam); Bmi1 (Cell Signaling Technology); Erk2 (gift from
Chris Marshall, Institute of Cancer Research); Stat1 (Cell
Signaling Technology). Alexa-Fluor680 (Molecular Probes) or
IRDye800 (Rockland)-conjugated secondary antibodies were
detected by infra-red imaging (Li-Cor Odyssey). Goat anti-
mouse and goat anti-rabbit horseradish peroxidase-conjugated
antibodies were from Pierce.
Histology and immunohistochemistry
Histology and immunohistochemistry were performed as
described.18 Antibodies and working concentrations used for
immunohistochemistry and immunoﬂuorescence were the fol-
lowing: LIMK2, 1:200 (Santa Cruz Biotechnology, Inc);
Phospho-Coﬁlin, 1:100 (Cell Signaling Technology); GFP, 1:250
(BD Biosciences); Texas-Red phalloidin, 1:250 (Molecular
Probes, Invitrogen); β-catenin, 1:1000 (BD Biosciences).
DAB-stained slides were imaged using a Hamamatsu
Nanozoomer NDP slide scanner (Hamamatsu Photonics) and
Digital Slide Server (Slidepath) software. For immunoﬂuores-
cence images a Nikon A1R confocal microscope was used. For
Drosophila immunoﬂuorescence, tissues were dissected in
phosphate-buffered saline (PBS) and ﬁxed for 30–45 min in 4%
para-formaldehyde. After ﬁxation, samples were washed three
times in PBS+0.1% Triton X-100 (PBST) and incubated in
primary antibodies overnight at 4°C. Samples were then washed
and subjected to secondary antibody staining for 2 h at room
temperature followed by washing and mounting on Vectashield
containing DAPI (Vector Laboratories, Inc). Primary and secondary
antibodies were incubated in PBST+0.5% bovine serum albumin.
The antibodies used were anti-phospho-Histone 3 (1:100 dilution,
from Cell Signaling Technology), anti-GFP (1:2000 dilution from
Abcam) and anti-Armadillo (1:3 dilution, developed by
E. Wieschaus and obtained from the Developmental Studies
Hybridoma Bank developed under the auspices of the National
Institute of Child Health and Human Development and main-
tained by the University of Iowa, Department of Biology, Iowa
City, IA, USA). Primary antibodies were visualised with Alexa 488,
Alexa 532 or 594-conjugated secondary antibodies (Molecular
Probes, Invitrogen).
Mice
Lgr5-EGFP-ires-Cre:ER-T2 (Lgr5>GFP) mice were described previ-
ously.19 Limk2 gene-trap embryonic stem cells (sequence tag:
RRE287; MMRRC stock # 001883-UCD) were obtained from
BayGenomics and used for blastocyst injections at the Beatson
Institute using standard methods. Experimental mice are from a
mixed C57BL/6J and 129/ola strain background. Limk2-KO mice
are viable and born at Mendelian ratios (observed genotype at birth
49/183=26.8%) with no macroscopic abnormalities. All proce-
dures were performed under appropriate licences and according to
the UK Home Ofﬁce guidelines.
Colitis-associated CRC (AOM+DSS)
On day 1, eight mice of each genotype (8–12-week-old littermates)
were weighed and injected intraperitoneally with 12.5 mg/kg of
azoxymethane (AOM) solution (Sigma-Aldrich). On day 6 the
drinking supply was ﬁlled with dextran sodium sulfate (DSS) solu-
tion (DSS salt, MW36 000–56 000 Da, MP Biomedicals). On day
8 the drinking supply was reﬁlled with DSS solution and on day 10
replaced with autoclaved water for 14 days. This cycle (5 days DSS
plus 14 days water) was repeated two more times. DSS regimes
were the following: cycle 1–1%; cycle 2–1.5%; cycle 3–1.5%. The
mice were culled and dissected on approximately day 70. Tumour
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volume was determined by assuming its quasi half-spherical
shapeV ¼ ½ð4=3pr3Þ=2.
Lgr5-GFP+ stem cell FACS sorting, RNA puriﬁcation and
quantitative reverse transcriptase PCR
Crypt-villus organoids removed from matrigel by centrifugation
or freshly isolated intestinal crypts were single-cell dissociated in
TrypLE (Life Technologies) combined with DNAse I (2000 U/
ml) for 30 min at 37°C. Dissociated cells were passed through a
40 mm cell strainer and incubated with DAPI (1:500) for dead
cell exclusion. DAPI−/GFP+-positive cells were analysed and
sorted using a FacsAria (BD Bioscience). Cells were sorted into
full organoid culture medium plus Y27632 (10 mM). RNA was
puriﬁed from approximately 5000 GFP+ cells using the
Arcturus PicoPure RNA isolation kit (Applied Biosystems).
Complementary DNA was synthesised using the Quantitect
Reverse Transcription Kit (Qiagen). Quantitative reverse tran-
scriptase (RT)-PCR primers for murine Limk2, Lgr5, Olfm4,
Ascl2, CD44, Bmi1, 18s and Hprt were acquired from Qiagen
(Quantitect Primer Assay).
X-gal staining of mouse frozen sections
Tumour and adjacent normal tissue specimens from Ah-CreER
APCFl/+ PTENFl/+ Limk2+/− mice were isolated, washed in PBS
and mounted with OCT (Tissue-Tek, Sakura) and immediately
frozen using Cryospray (CellPath Ltd). Twelve to 14 mm thick-
ness sections were stained using the β-Gal Staining Kit
(Invitrogen, Life Technologies) for 48 h at 37°C.
Flies
Fly cultures and incubations were carried out on standard
molasses media, with food changes every 2 days, at 25°C with
controlled 12 h light-dark cycles as described in.20 For RNAi
experiments, male dLIMK IR 26 294 or 28 948 ﬂy lines were
crossed with virgin female dicer;esg-gal4>GFP;gal80 ﬂies. F1
females were collected for incubation at 29°C for 14 days to see
effect of RNAi. All initial Drosophila stocks used were described
previously and were obtained from the Bloomington Drosophila
Stock Center.
Human tissue microarrays
A CRC tissue microarray (TMA) was constructed containing
normal colon mucosa (n=50), primary (n=650) and metastatic
CRC (n=285) as previously described in O’Dwyer et al,21
Hope and Murray22 and Murray et al.23 The metastases were
all lymph node metastasis from the corresponding stage 3
(Dukes C) cancers. The histopathology of the cancers was
reported as previously described,21 22 and clinicopathological
details are summarised in supplementary table S1 (available
online only). The authors conﬁrm that all tissue samples were
collected under strict institutional review board-approved guide-
lines/protocols with informed consent (National Research Ethics
Service, North of Scotland ref. nos. 08/S0801/81 and 11/NS/
0015). All collected human tissues were treated under strict con-
ﬁdentiality and according to appropriate applicable laws that
protect the conﬁdentiality of personal information. No names
or any other identity information were revealed during the
development of tissue arrays, nor to end users, and as a result
are exempt from consideration by the Beatson Institute
Committee on Human Subjects in Medical Research due to
being anonymised and non-traceable. Cancer Research UK
guidelines were followed in the handling and analysis of this
material.
Statistical analysis
Unless indicated, statistical signiﬁcance was determined by one
way analysis of variance followed by Tukey’s post-hoc tests.
Data are shown as means±SD unless indicated. Box plots indi-
cate medians bounded by quartiles with whiskers denoting 5th–
95th percentiles. Survival analysis was performed with SPSS
V.19 using the method of Kaplan–Meier and the log-rank test to
compare individual groups.
RESULTS
LIMK2 expression in human CRC
To determine whether LIMK2 protein levels were affected in
CRC cell lines, we ﬁrst validated the speciﬁcity of an antibody
that recognises both LIMK2a and LIMK2b variants17 by western
blotting lysates from wild-type Limk2+/− and Limk2−/− mouse
embryo ﬁbroblasts (ﬁgure 1A; non-speciﬁc band denoted by*).
Western blotting lysates from a panel of CRC cell lines revealed
that expression of LIMK1, ERK2 and the LIM kinase substrate
coﬁlin were relatively constant, while LIMK2 expression was
variable in numerous cell lines (ﬁgure 1B). LIMK2 expression in
HCT116 and SW48 cells was lower compared to normal human
colon tissue (ﬁgure 1C) on a protein lysate mass/mass basis (ﬁrst
and second vs third lane) or when normalised to α-tubulin levels
(vs fourth lane). To determine whether epigenetics might be
inﬂuencing LIMK2 expression, we chose SW48 cells as an exem-
plar and treated them with the de-novo methyltransferase inhibi-
tors RG108 or 5-Aza.24 Both treatments showed elevated
LIMK2 levels within 48 h (ﬁgure 1D). Sequencing of bisulﬁte
converted genomic DNA revealed methylation of the 7 CpG
islands (positions indicated by vertical red lines in the ﬁgure 1D
line diagram) in the LIMK2a promoter (−629 to −541 relative to
the start of transcription) and the seven CpG islands in the
LIMK2b promoter (+104 to +314) that were reduced by 5-Aza
treatment (ﬁgure 1D, pie charts represent results from 10 inde-
pendent DNA isolates). We next analysed LIMK2 gene expression
from CRC microarray datasets obtained using Oncomine.25
There were statistically signiﬁcant decreases in LIMK2 expression
in adenocarcinoma samples from caecum, colon, colon mucin-
ous, rectal, rectal mucinous and rectosigmoid tissue relative to
normal colon tissue (ﬁgure 1E; left side;26 right side).
27
LIMK2
gene expression was also signiﬁcantly lower in lamina proprial or
epithelial adenomas and carcinomas relative to matched normal
cells that had been separated by laser capture microdissection
from normal, adenoma and carcinoma samples28 (ﬁgure 1F).
Similarly, LIMK2 expression was signiﬁcantly lower in carcin-
omas relative to normal colorectal samples in two independent
studies (ﬁgure 1G;
28
right side).
29
These results indicate
that LIMK2 gene expression is frequently and signiﬁcantly
reduced in CRC.
We next examined Limk2 levels in murine normal intestines
and intestinal tumours from genetically modiﬁed cancer-prone
mice. We observed Limk2 expression throughout the intestines
of wild-type mice, with highest levels at the base of crypts
(ﬁgure 2A), which under higher magniﬁcation were found also
to be marked by expression of GFP driven by the promoter of
the stem cell marker Lgr519 (ﬁgure 2B, upper panels). Similarly,
in colon sections Limk2 was found throughout with a degree of
overlap with Lgr5 expressing cells (ﬁgure 2B, lower panels).
Importantly, these staining patterns were absent in mice homo-
zygous for gene-trapped Limk2 loci (ﬁgure 2A,B), thereby valid-
ating this antibody for use in immunohistochemistry. To
determine whether Limk2 deletion was associated with reduced
signalling output, we stained sections with an antibody that
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detects phosphorylation of the Limk2 substrate coﬁlin,
which we previously validated for coﬁlin protein and phosphor-
ylation speciﬁcity.30 Similar to Limk2, pCﬂ was localised
throughout the intestinal cells with highest levels at the base of
the crypts, which was clearly reduced in the Limk2-KO sections
(ﬁgure 2C).
We next examined Limk2 expression in intestinal tumours
from the two-hit genetically modiﬁed mouse model that
Figure 1 Limk2 expression in human colorectal cancers (CRC). (A) Western blot of mouse embryo ﬁbroblast cell lysates from indicated genotyptes.
*Non-speciﬁc band (B) Western blot of human CRC cell lysates. (C) Western blot of two CRC cell line and normal human colon lysates. Equivalent
protein amounts were run in the three left lanes, equivalent α-tubulin amounts were run in the ﬁrst two left lanes and last right lane. (D) Western
blot of SW48 cell lysates following 48 h treatment with indicated de novo methyltransferase inhibitor. CpG methylation in LIMK2a and LIMK2b
promoters without or with 5-azacytidine treatment. Line diagrams indicate position of CpG islands (red lines within boxed region) relative to the
transcriptional start site for each promoter. Pie charts indicate proportion of methylation from multiple independent clones for each CpG island.
(E) Log2 median-centred LIMK2 messenger RNA expression in indicated normal versus adenocarcinoma tissue samples from; left side26 right side.27
(F) Log2 median-centered LIMK2 mRNA expression in indicated microdissected normal lamina propria or epithelia, versus corresponding adenoma or
carcinoma samples from Skrzypczak et al.28 (G) Log2 median-centered LIMK2 mRNA expression in normal versus carcinoma samples from left side,28
right side.29 LIMK2, LIM kinase 2.
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requires stochastic loss of heterozygosity for Apc and Pten.31
Limk2 expression in Ah-Cre:ER, ApcFl/+, PtenFl/+ mice was
markedly lower in tumours than in surrounding normal tissue
(ﬁgure 2D; tumour border outlined with red dashed line). Mice
bearing one copy of a β-galactosidase gene-trap in the Limk2
locus in the context of a Ah-Cre:ER, ApcFl/+, PtenFl/+ genotype
showed reduced β-galactosidase activity (visualised with X-gal)
in dysplastic crypts compared to normal crypts, indicating inhib-
ition of Limk2 promoter transcriptional activity (ﬁgure 2E).
These data indicate that the apparently high expression of
Limk2 in mouse intestinal cells becomes repressed, probably via
promoter methylation and consequent inhibition, during
tumorigenesis.
To determine how the patterns of LIMK2 expression changes
are associated with oncogenesis and tumour progression, we
used the LIMK2 antibody to stain representative human intes-
tinal adenoma samples. Similar to normal tissue, LIMK2 expres-
sion was relatively high in low grade adenomas but markedly
Figure 2 Limk2 expression in mouse intestine and tumours. (A) Limk2 expression (red) in intestine sections from wild-type (WT) or Limk2 knockout
(KO) mice (B) Intestine or colon sections as indicated from WT or Limk2-KO mice that had been crossed with Lgr5>GFP mice were cut and stained
for Limk2 (red) expression. Merged image also has DAPI staining of cell nuclei. (C) Intestine sections from WT or Limk2-KO mice were cut and
stained for phosphorylated coﬁlin (pCﬂ; red). Merged image also has DAPI staining of cell nuclei. (D) Immunohistochemical analysis of Limk2
expression in intestinal tumour and adjacent normal tissue from Ah-Cre:ER, ApcFl/+, PtenFl/+ mouse. (E) β-Galactosidase activity in normal and
dysplastic crypts as detected by X-gal staining of frozen intestinal tissue sections from heterozygous Limk2 gene-trap, Ah-Cre, ApcFl/+, PtenFl/+ mice.
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decreased in high grade adenomas with low or high levels of
dysplasia (ﬁgure 3A). We next stained a well-characterised TMA
comprised of 650 patient samples of normal intestines and
tissue from Dukes A to Dukes C tumours, as well as representa-
tive lymph node metastases.21 By assigning staining intensity
scores from 1 (low) to 6 (high), we established that median
staining intensity in normal intestines scored 5 with relatively
little variation (ﬁgure 3B,C). LIMK2 expression progressively
dropped in tumours, with each Dukes stage having signiﬁcantly
lower LIMK2 expression than its predecessor (ﬁgure 3B,C, see
supplementary table S2, available online only). LIMK2 expres-
sion in lymph node metastases was signiﬁcantly lower than all
stages except Dukes C (ﬁgure 3B,C, see supplementary table S2,
available online only). To determine the association between
LIMK2 expression and survival, we grouped staining categories
into low (scores 1–3) or high (scores 4–6) and found that
patients with low LIMK2 expression had signiﬁcantly
(χ2=14.51, p<0.001; log rank Mantel–Cox test) lower mean
survival times (93.9 months) than high LIMK2 expressing
patients (118.2 months) (ﬁgure 3D and see supplementary table
Figure 3 LIM kinase 2 (LIMK2) expression in human colorectal cancer (CRC) progression. (A) Immunohistochemical analysis of LIMK2 expression in
human intestinal low grade and high grade adenomas. (B) Immunohistochemical analysis of LIMK2 expression in a tissue microarray (TMA) of
human colorectal tumours and lymph node metastases. (C) LIMK2 staining intensities from TMA of human CRC. (D) Cumulative survival curves for
high and low LIMK2 expressing patients.
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S3, available online only). When the median and mean survival
times were estimated for each scoring rank, there was a clear
trend from highest survival for patients scoring 6 to lowest sur-
vival for patients scoring 1 (see supplementary table S4, avail-
able online only). To determine whether reduced LIMK2
expression levels were associated with lower signalling output,
we stained the TMA with the antibody that detects coﬁlin phos-
phorylation.30 Levels of pCFL were signiﬁcantly and progres-
sively reduced relative to normal intestine and through each
Dukes stage, with the exceptions that pCFL in Dukes B tumours
did not differ from Dukes A, nor did pCFL in lymph node
metastases differ from Dukes C tumours (ﬁgures 4A,B, see
supplementary table S5, available online only). Mean patient
survival was signiﬁcantly (χ2=14.81, p<0.001; log-rank
Mantel–Cox test) longer in high pCFL patients (119.3 months)
than in low pCFL patients (91.2 months) (ﬁgure 4C and see
supplementary table S6, available online only). When the
median and mean survival times were estimated for each pCFL
scoring rank, there was a clear trend from highest survival for
patients scoring 6 to lowest survival for patients scoring 1 (see
supplementary table S7, available online only). When examining
on a patient by patient basis, there was an obvious correlation
between LIMK2 expression and pCFL levels (ﬁgure 5A), which
when compared using the SlidePath tissue image analysis system
positive pixel algorithm32 33 yielded a Pearson product–moment
correlation coefﬁcient of r=0.59 (ﬁgure 5B). When both
LIMK2 and pCFL variables were analysed together, best patient
mean survival time was for high LIMK2 and pCFL
(118.9 months, 38.7% of total patients; ﬁgure 5C, see supple-
mentary table S8, available online only), while worst mean sur-
vival time was for low LIMK2 and pCFL (84.6 months, 36.1%
of total patients; ﬁgures 5C, see supplementary table S8, avail-
able online only). These data reveal clear patterns of reduced
LIMK2 expression and activity in CRC, and a signiﬁcant associ-
ation with patient mortality.
LIMK2 promoter methylation in human tumours
The DNMT inhibitor-sensitive promoter methylation in a CRC
cell line (ﬁgure 1D) suggested that a similar effect on promoter
methylation might account for the reduction in LIMK2 expres-
sion in human tumours (ﬁgure 3). By isolating genomic DNA
from six frozen tumour sections represented in the TMA along
with matched normal tissue isolated from these patients, we
were able to compare patterns of promoter methylation using
bisulﬁte sequencing. The seven CpG islands in the LIMK2a and
LIMK2b promoters were typically more methylated in tumours
than matched normal tissues (results from one patient example
depicted in ﬁgure 6A). When percentages of CpG island
Figure 4 Phosphorylated coﬁlin in human colorectal cancer (CRC) progression. (A) Immunohistochemical analysis of pCFL expression in a tissue
microarray (TMA) of human colorectal tumours and lymph node metastases. (B) pCFL staining intensities from TMA of human CRC. (C) Cumulative
survival curves for high and low pCFL-expressing patients.
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methylation for LIMK2a and LIMK2b promoters were compiled
from six patients, there was signiﬁcantly higher CpG methyla-
tion in tumours compared to matched normal tissues. These
results support the conclusion that reduced LIMK2 expression
in human CRC is due to increased promoter methylation.
Stem cell homeostasis in D melanogaster midgut
To understand how repression of LIMK2 expression might con-
tribute to CRC, we used D melanogaster as a genetically tract-
able model system to examine the role of LIM kinase in
gastrointestinal homeostasis.34–36 Importantly, experiments in
the Drosophila posterior midgut, which is homologous to the
mammalian intestine, have established that the orthologues of
genes frequently mutated in human CRC (eg, APC, β-catenin,
etc.) play important roles in the regulation of intestinal stem
cell proliferation and tissue homeostasis.37–39 We used
inverted-repeat RNA interference transgenes (RNAi) under the
transcriptional control of the Gal4/UAS (upstream activating
sequence) system40 to reduce expression of the single
Drosophila LIM kinase homologue (dLIMK) in stem cells
expressing the transcription factor Gal4 driven by the escargot
(esg) promoter.41 When dLIMK was knocked down by esg-Gal4
driven expression of UAS-dLIMK RNAi in ﬂies also carrying a
UAS-GFP transgene to mark stem cells, it was readily apparent
that, compared to control ﬂies (wild-type), dLIMK knockdown
signiﬁcantly increased the proportion of GFP-expressing stem
cells/progenitor cells (ﬁgure 7A,B) that were also demarcated by
their relatively elevated expression of the β-catenin homologue
Armadillo and Delta (ﬁgure 7C). This phenotype is consistent
with increased stem cell proliferation.42 To measure whether
dLIMK reduction affected cell proliferation directly, ﬁxed
midguts were stained with phosphorylated Histone 3 (pH3)
antibody as a marker of mitotic cells.41 While pH3 staining was
very low to absent in midguts from wild-type ﬂies under
homeostatic conditions, dLIMK knockdown with two independ-
ent RNAi transgenes signiﬁcantly (p<0.001) increased the
mean number of pH3-positive cells relative to the control geno-
type by more than ﬁvefold (ﬁgure 7D,E). Co-staining with DAPI
revealed patterns of condensed chromatin that supported the
conclusion that pH3-positive cells were mitotic (ﬁgure 7D, right
panels). Haematoxylin and eosin (H&E) stained cross-sections
of parafﬁn-embedded posterior midguts from control ﬂies were
typical in their appearance, with a thin continuous cell layer sur-
rounding a substantial lumen (ﬁgure 6D, left panel). In contrast,
H&E stained midgut cross-sections from UAS-dLIMK RNAi ﬂies
were signiﬁcantly thicker (ﬁgure 6D, right panel, ﬁgure 7G).
These data indicate that in Drosophila, LIM kinase normally
contributes to intestinal homeostasis by limiting the proliferation
of stem cells.
LIMK2 deletion increases Lgr5-positive mouse intestinal
stem cells
We next wished to determine whether there was a conserved
role for Limk2 in regulating mouse intestinal stem cell homeo-
stasis. Using a method that allows for the isolation and long-
term in-vitro propagation of self-renewing intestinal epithelial
cells,15 we examined whether Limk2 deletion affected prolifer-
ation of the Lgr5-positive stem cell population.19 When initially
Figure 5 Association of LIM kinase 2 (LIMK2) expression and coﬁlin phosphorylation with patient outcomes. (A) Staining for LIMK2 and pCFL from
paired patient sections. (B) LIMK2 and pCFL staining intensities were measured using SlidePath tissue image analysis system positive pixel
algorithm.32 33 (C) Distribution of outcomes for all combinations of high and low LIMK2 and pCFL.
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isolated from wild-type or Limk2-KO mice, intestinal epithelial
cells showed no signiﬁcant differences in the expression of
various stem cell markers by western blotting or RNA micro-
array (see supplementary ﬁgure S1A,B, available online only),
while the percentages of Lgr5>GFP-expressing cells also did
not signiﬁcantly differ (see supplementary ﬁgure S1C, available
online only). However, when cells were cultured and passaged
twice (every 7 days) in the presence of the proliferation-inducing
growth factors epidermal growth factor, R-spondin1 and
Noggin while embedded in three-dimensional Matrigel, there
was a greater proportion of Lgr5>GFP-positive cells in the
Limk2-KO organoids relative to wild-type as revealed by
immunoﬂuorescence microscopy (ﬁgure 8A; white arrows illus-
trating example GFP-positive cells). When cells from multiple
independent organoids were dissociated and GFP-expressing
cells counted by FACS (ﬁgure 8B, 10 000 events gated per con-
dition), there was a signiﬁcant (p<0.05, Student’s t test)
increase in the percentage of Lgr5>GFP-positive stem cells in
the Limk2-KO relative to wild-type (ﬁgure 8C). Western blotting
lysates from multiple independent organoids corroborated the
elevation of Lgr5 driven GFP expression (indicating a greater
proportion of GFP-positive cells) in the Limk2-KO (ﬁgure 8D).
When GFP-positive cells were isolated and collected by ﬂow
cytometry, RT-PCR analysis revealed no signiﬁcant differences
in the expression of a number of stem cell markers including
Lgr5, Bmi1, Olfm4, CD44 and Ascl2 between the wild-type and
Limk2-KO, indicating equivalent levels of ‘stemness’ of the
GFP-positive cells from each genotype (ﬁgure 8E). These results
indicate that under conditions that strongly promote the prolif-
eration of intestinal stem cells, the deletion of Limk2 provides a
competitive advantage relative to wild-type cells, giving rise to
an increased number of cells that are indistinguishable from
their wild-type stem cell counterparts. By inference, epigenetic
modiﬁcations to the LIMK2 promoters that resulted in tran-
scriptional repression could be positively selected for in human
CRC due to the increased response of stem cells to inducers of
proliferation.
Limk2 deletion promotes crypt dysplasia and tumour size in
a mouse model of colitis-associated CRC
To test the effect of LIMK2 deletion in a mouse model of
colitis-associated CRC, 6–12-week-old mice were injected with
a single dose of AOM (12.5 mg/kg), a potent carcinogen that
induces the formation of O6-methyl-guanine, followed by three
cycles of DSS administration in the drinking water (ﬁgure 9A).
DSS administration will cause chronic inﬂammation, enhancing
the incidence of AOM-induced tumours.43 Limk2-deﬁcient
mice display a higher sensitivity to the AOM+DSS protocol
with a signiﬁcant increase in weight variation (ﬁgure 9B,C),
reﬂecting the increased weight loss after the second and third
DSS cycles. At the end of the treatment regimen, Limk2-KO
mice had a marked increase in crypt-villus dysplasia and hyper-
plasia throughout the middle to distal colon (ﬁgure 9D). The
caecum also displayed a more severe dysplastic and hyperproli-
ferative phenotype, which is a less common feature of this
tumour model (ﬁgure 9D,E). There was a marked trend
towards a higher tumour incidence in Limk2-KO mice (ﬁgure
9F). The tumours were mostly adenomas with high β-catenin
expression. The most striking and signiﬁcant effects were on
the histology and volume of the β-catenin-positive tumour foci
in the Limk2-KO mice. Limk2-KO foci were signiﬁcantly larger
(ﬁgure 9G) and locally invasive, showing a higher grade of
Figure 6 CpG methylation of LIMK2a and LIMK2b promoters in normal and tumour tissue. (A) Line diagrams indicate position of CpG islands (red
lines within boxed region) relative to the transcriptional start site for each promoter. Pie charts indicate proportion of methylation from multiple
independent clones for each CpG island in the genomic DNA of a representative patient. (B) Cumulative LIMK2a and LIMK2b promoter methylation
data from matched normal and tumour tissue derived from six patients.
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dysplasia (ﬁgure 9E,G). These results indicate that the
removal of Limk2 in a colitis-associated CRC mouse model
had a mild effect on tumour initiation, but had a signiﬁcant
impact on tumour growth and on the acquisition of a more
invasive phenotype. This could be a due to the relief of a
proliferative constraint on gastrointestinal stem cells under con-
ditions that favour their continuous self-renewal, thus contrib-
uting to CRC.
DISCUSSION
We found that LIMK2 expression was reduced in the intestinal
tumours of cancer-prone genetically modiﬁed mice, as well as in
human CRC cell lines and tumours. To gain insight into the
potential roles of LIMK2, we undertook genetic analysis in the
Drosophila midgut, which is emerging as an informative model
for gastrointestinal homeostasis and tumorigenesis,44 and using
intestinal epithelial cells isolated from genetically modiﬁed mice.
These studies revealed a conserved role for LIMK2 in constrain-
ing gastrointestinal stem cells in Drosophila and mice, such that
relief of this constraint allowed for the expansion of stem cell
numbers. Given that accumulating evidence indicates that stem
cells are the predominant cells of origin for colorectal
tumours,2–5 a logical conclusion of this study is that there is a
positive selection for reduced LIMK2 expression and/or activity
during CRC initiation and progression to allow propagation of
gastrointestinal stem cells. Consistent with this conclusion,
genetic deletion of Limk2 to reduce its expression in the AOM/
DSS colitis-associated CRC mouse model resulted in increased
average intestinal tumour volume and a more severe dysplastic
and hyperproliferative phenotype.
Figure 7 Knockdown of dLIMK
increases Drosophila intestinal stem
cell proliferation and tissue thickening.
(A) Fly intestinal stem and progenitor
cells are marked by esg-driven GFP
and endogenous Armadillo (red)
expression, ﬂies expressing dLIMK
RNAi inverted repeat hairpins have
increased stem cell numbers compared
to the control genotype (wild-type;
WT). (B) GFP/DAPI-positive cells were
counted in ﬁve sections from ﬁve WT
and two dLIMK siRNA ﬂy lines.
(C) Cells expressing esg>GFP were also
marked by their elevated expression of
Armadillo and Delta relative to
neighbouring cells. (D) Proliferation
determined by staining for the mitotic
marker phosphorylated Histone 3
(pH3) in control (WT) or dLIMK
targeting RNAi. Higher magniﬁcation
images of pH3 and DAPI staining
reveal the appearance of condensed
chromosomes in these mitotic cells.
(E). Quantiﬁcation of pH3 numbers in
ﬂies expressing two independent
dLIMK RNAi hairpins revealed
statistically signiﬁcant increases relative
to control WT ﬂies. (F) Cross-sections
of ﬁxed and H&E stained midguts from
control (WT) or dLIMK RNAi-expressing
ﬂies. (G) Average gut wall widths
determined from four separate
measurements for each cross-section
from ﬁve WT and dLIMK RNAi ﬂies.
*p<0.05 by Student’s t test.
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The reduced LIMK2 expression in CRC was surprising given
the reports of elevated LIM kinase expression in other cancers
including breast,10 11 malignant melanoma12 and prostate13
tumours. Because of the role of LIM kinases in regulating acto-
myosin cytoskeletal dynamics, it has been assumed that there
would consistently be elevated LIM kinase expression in
advanced cancers to drive local invasion and distant metastasis.
Indeed, we showed that inhibition of LIM kinase activity by
RNAi or chemical inhibition blocked the collective invasion of
breast cancer and squamous cell carcinomas by blocking the
invasive ability of leading cells using in-vitro three-dimensional
invasion models.45 However, by focusing on how LIM kinase
activity inﬂuences processes involved in cell motility and
invasion, reports of negative roles of LIM kinase on functions
such as cell cycle regulation may have been overlooked.
Elevated LIMK2 levels following DNA damage were found to
promote G2/M arrest via coﬁlin,
46 which is consistent with a
proposed role for LIMK2 during mitosis in regulating micro-
tubule organisation and spindle orientation.47 48 Given that
expression of the LIMK2a and LIMK2b variants has also been
reported to be reduced in thyroid cancers,46 it will be important
to re-consider how LIMK2 contributes to speciﬁc cancers rather
than attempting to construct a uniﬁed theory.
In actual fact, the role of LIM kinases in regulating coﬁlin
phosphorylation and ﬁlamentous actin turnover is nuanced, and
in some circumstances it may actually be more favourable for
Figure 8 Limk2 deletion increases
cultured mouse intestinal stem cell
proportion. (A) Self-renewing intestinal
epithelial cells were isolated from
wild-type (WT) and Limk2 knockout
(KO) mice and propagated in vitro in
the presence of the growth factors
EGF, R-spondin1 and Noggin while
embedded in three-dimensional
Matrigel. Organoids were ﬁxed,
stained for ﬁlamentous actin with
phalloidin, and visualised for
Lgr5-driven GFP expression and
phalloidin staining by confocal
microscopy. (B) Organoids were
isolated and disrupted to yield single
cell suspensions. After a brief
incubation with propidium iodide (PI),
FACS analysis of 10 000 PI-negative
live cells was used to determine the
proportion of Lgr5>GFP-positive cells
in each genotype. (C) Graph of results
from three independent FACS
experiments. *p<0.05 by Student’s t
test. (D) Equivalent cell numbers from
disrupted organoids of intestinal
epithelial cells from WTand Limk2 KO
mice were used to prepare whole cell
lysates that were western blotted as
indicated. (E) RT-PCR analysis of stem
cell marker expression in sorted
GFP-positive cells from WT and
Limk2-KO mice expressing Lgr5>GFP.
The expression levels of each indicated
stem cell marker did not vary
signiﬁcantly between the WT and
Limk2-KO mice, indicating equivalent
‘stemness’.
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increased invasive ability for there to be reduced LIM kinase
expression and activity. We previously found that ectopic expres-
sion of LIMK1 decreased the motility of Ras-transformed Swiss
3T3 ﬁbroblasts,49 while overexpression of LIMK1 in MTLn3
rat mammary carcinoma cells inhibited lamellipod extensions,50
EGF-stimulated motility, and in vivo invasion.51 The relative
proportions of LIM kinase and coﬁlin, as well as the activity of
coﬁlin phosphatases such as Slingshot, contribute to regulating
the coﬁlin activity cycle that is the key determinant of invasive
and metastatic potential.52 53 The continuous decreases in
LIMK2 expression and coﬁlin phosphorylation with advancing
tumour grade suggests that, in addition to the effects on
gastrointestinal stem cells, there may be additional contributions
of reduced LIMK2 signal output ion promoting tumour cell inva-
siveness. As a result, there may actually be two distinct ways that
the reduction in LIMK2 expression contributes to CRC; through
relief of constraints on stem cells early in tumorigenesis, and by
promoting cell invasiveness during more advanced stages.
An inference from this study is that because LIMK2 levels
are decreased in a sizeable proportion of CRC patients, these
cancers might be more effectively treated with some che-
motherapeutics because knocking down and/or inhibiting
LIMK2 sensitises cancer cells to DNA damaging agents,17
Aurora A inhibitors,54 Ras inhibition55 and microtubule-
Figure 9 Limk2 deletion increases
tumour volume and dysplasia in a
colitis-associated colorectal cancer
mouse model. (A). Timeline of
experimental procedure. (B) Mean
weights of wild-type and Limk2
knockout mice during the experimental
procedure relative to starting weight
(100%). (C) Coefﬁcient of variation in
weight curves for wild-type and Limk2
knockout mice. *p<0.05 by Student’s t
test. (D) Cross-sections of colon and
caecum from wild-type and Limk2
knockout mice as indicated. Boxes
indicate regions depicted in higher
magniﬁcation images. (E) Serial
sections of colon tissue from wild-type
and Limk2 knockout mice as indicated.
Boxes indicate regions depicted in
higher magniﬁcation images. Elevated
β-catenin staining relative to
surrounding tissue was used to identify
tumours and deﬁne dimensions.
(F) Number of β-catenin-positive foci
per colon section from wild-type and
Limk2 knockout mice as indicated. p
Value by Student’s t test. (G) Volume
of β-catenin-positive foci from
wild-type and Limk2 knockout mice as
indicated. *p<0.05 by Student’s t test.
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destabilising drugs such as vincristine and vinblastine.56
Therefore, knowledge of LIMK2 expression levels in CRC may
have utility in patient stratiﬁcation for the development of per-
sonalised therapies.
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